Reports
Reports
Rising prevalence of Down syndrome cases and growing maternal age and associated chromosomal risks are driving the non-invasive prenatal testing market demand. Moreover, physicians are choosing advanced DNA-based screening methods like NIPT due to their high safety, accuracy, and early screening for chromosomal abnormalities in pregnancy.
Compared to invasive testing procedures like amniocentesis with a risk of complications, NIPT is a non-invasive testing procedure that provides accurate findings, making it a procedure of choice among physicians and expectant couples alike.
In line with the latest non-invasive prenatal testing market trends, key players are actively forming partnerships and collaborations to strengthen their market position amid increasing competitionter in countries like the Netherlands, and upcoming reimbursement plans in Germany for screening Down syndrome, are further boosting the adoption of NIPT across various regions.
Non-invasive Prenatal Testing, or NIPT, is a test performed during pregnancy to asess the risk of certain genetic conditions in a fetus. It is performed by analyzing small fragments of fetal DNA in the mother's blood, usually as early as week 10 of pregnancy. Unlike invasive procedures such as amniocentesis or chorionic villus sampling (CVS), NIPT is not harmful to the fetus in any way because it is just a routine blood test on the mother.
NIPT is primarily used in the detection of chromosomal disorders such as Down syndrome (trisomy 21), trisomy 18, and trisomy 13. Additionally, it also helps in detecting the sex of the baby and, in some cases, screen for other genetic diseases.
| Atribute | Detail |
|---|---|
| Market Drivers |
|
High incidence rate of babies born with Down’s syndrome and Turners’ Syndrome globlly is likely to drive the demand for non-invasive prenatal testing (NIPT), primarily due to the high level of accuracy and safety it offers over conventional screening and invasive diagnostic methods. Conventional screening methods, such as nuchal translucency scan and maternal serum screening, are non-invasive in nature; however, these tests are not largely preferred due to their low level of accuracy.
On the other hand, invasive prenatal testing methods such as amniocentesis and chorionic villus sampling (CVS) show 100% accuracy, but the associated risk of miscarriage deters many patients from opting for them. In such a scenario, growing prevalence of Down syndrome across the globe is likely to boost the demand for NIPT such as MaterniT21 PLUS, Harmony, verify, Panorama, and NIFTY.
According to sources from Down’s syndrome Education (DSE) International, the prevalence of Down syndrome ranges from 1 in 1,500 to 1 in 400 babies born across different countries. The organization further reported that nearly 220,000 babies are born with Down’s syndrome globally every year. According to the Centers for Disease Control and Prevention (CDC), the incidence rate is 1 in every 700 child births (around 6,000 annually) in the U.S. On the other hand, 1-734 per 100,000 live births were detected from Down’s syndrome, revealed by the WHO.
Globally, the average age of first-time mothers is increasing, especially in developed countries such as U.S., U.K., France, Germany, Italy, and Japan. Financial stability, rising literacy rates, and social factors are key factors responsible for the advancing maternal age. The risk of fetal chromosomal abnormalities is directly related to the rise in maternal age.
According to the American Academy of Family Physicians (AAFP), the risk of fetal chromosomal abnormalities increases gradually up to the age of 30, then rapidly beyond that. According to the source, the chance of Down's syndrome in the newborn is 1/1,300 up to 25 years of maternal age, while the risk increases to 1/365 in pregnant women at 35 years of age and to 1/30 after 40 years. This rising trend in maternal age is thus, anticipated to result is higher incidence of chromosomal abnormalities, thereby driving the demand for Non-invasive Prenatal Testing (NIPT) as a safer and more accurate alternative to conventional testing methods.
Based on end-user, the global non-invasive prenatal testing market has been divided into hospitals, diagnostic laboratories, specialty clinics, and others.
The diagnostic laboratories segment is anticipated to expand at a significant growth rate during the forecast period, due to the emerging healthcare infrastructure in the diagnostic laboratories as compared to hospitals.
Moreover, the presence of several diagnostic laboratories offering NIPT across the globe is also fueling market growth. Labs such as MedGenome Labs Ltd. offer MedGenome Claria NIPT tests for the diagnosis of Trisomies 21, 18, and 13; Monosomy X; and other sex chromosomal abnormalities.
Similarly, Claria NIPT Plus offered by MedGenome is used to detect Down Syndrome; Edwards’ Syndrome; Patau Syndrome; Triploidy; Monosomy X (Turner Syndrome); Klinefelter Syndrome, Triple X; Jacob’s Syndrome; 22q11.2 Deletion Syndrome; 1p36 Deletion Syndrome; Prader-Willi Syndrome; Angelman Syndrome; and Cri-du-chat Syndrome.
| Atribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest non-invasive prenatal testing industry analysis, North Americas dominated the market with approximately 60% share in 2024, followed by Europe. High rate of diagnosis and treatment of trisomy disorders, strong healthcare infrastructure, and the presence of key companies in the U.S., are some of the factors driving the non-invasive prenatal testing market share in region.
For instance, in May 2024, Natera introduced a cfDNA-based fetal RhD test, offering a non-invasive method to determine fetal RhD status as early as nine weeks gestation. This test achieved 100% sensitivity and over 99% specificity in a validation study involving more than 650 RhD-negative pregnancies.
Additionally, the Asia Pacific non-invasive prenatal testing market is projected to expand at the fastest CAGR during the forecast period, driven by several key factors. The rising average maternal age across the region is contributing to an increased incidence of chromosomal aneuploidies in newborns, thereby expanding the potential customer base for NIPT.
Furthermore, significant advancements in countries like China and Japan, the technological integration of next-generation sequencing (NGS) techniques, and continuous improvements in healthcare infrastructure are collectively supporting robust market growth across Asia Pacific.
This market is consolidated due to the broad range of product offerings and strong distribution network of key entities in emerging and developed countries. In addition, companies are undertaking several strategic initiatives, including partnerships, mergers, acquisitions, and product expansions, to strengthen their market position.
Each of these players has been profiled in the non-invasive prenatal testing market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Atribute | Detail |
|---|---|
| Market Size Value in 2024 | US$ 4.7 Bn |
| Market Forecast Value in 2035 | US$ 13.2 Bn |
| Growth Rate (CAGR) for 2025 to 2035 | 9.5% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn |
| Market Analysis | It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 4.7 Bn in 2024.
The global non-invasive prenatal testing business is projected to reach more than US$ 13.2 Bn by the end of 2035.
Rising prevalence of Down syndrome cases and growing maternal age and associated chromosomal risks.
It is anticipated to grow at a CAGR of 9.5% from 2025 to 2035.
North America was the leading region in 2024.
F. Hoffmann-La Roche Ltd., Natera, Inc., PerkinElmer Inc., IGENOMIX, Eurofins Scientific, Illumina, Inc., Pacific Biosciences, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Berry Genetics Inc. are the prominent players in the non-invasive prenatal testing market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Non-invasive Prenatal Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, 2020 to 2035
5. Key Insights
5.1. Technological Advancements
5.2. Pricing Trends
5.3. Regulatory Landscape across Key Regions / Countries
5.4. PORTER’s Five Forces Analysis
5.5. PESTEL Analysis
5.6. Value Chain Analysis
5.7. Key Purchase Metrics for End-users
5.8. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
5.9. Benchmarking of the Product Offered by the Competitors
6. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Test Type, 2020 to 2035
6.3.1. Cell-Free DNA Screening Test
6.3.2. Serum Marker Screening Test
6.3.3. Neural Tube Defects Test
6.3.4. Ultrasonography
6.4. Market Attractiveness By Test Type
7. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Product, 2020 to 2035
7.3.1. Instruments
7.3.2. Kits & Reagents
7.4. Market Attractiveness By Product
8. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Technology, 2020 to 2035
8.3.1. Whole-Genome Sequencing
8.3.2. SNP Analysis
8.3.3. Microarray Analysis
8.3.4. Rolling Circle Amplification
8.4. Market Attractiveness By Technology
9. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Indication, 2020 to 2035
9.3.1. Down Syndrome (trisomy 21)
9.3.2. Edwards syndrome (trisomy 18)
9.3.3. Patau syndrome (trisomy 13)
9.3.4. Turner Syndrom (Monosomy X/XO)
9.3.5. Klinefelter Syndrome (XXY)
9.3.6. Jacob's Syndrome (XYY)
9.3.7. Gender Identification
9.3.8. Others (Triple X, etc.)
9.4. Market Attractiveness By Indication
10. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By End-user, 2020 to 2035
10.3.1. Hospitals
10.3.2. Specialty Clinics
10.3.3. Diagnostics Laboratories
10.3.4. Others (Research Institutes, etc.)
10.4. Market Attractiveness By End-user
11. Global Non-invasive Prenatal Testing Market Analysis and Forecasts, By Region
11.1. Key Findings
11.2. Market Value Forecast By Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness By Region
12. North America Non-invasive Prenatal Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Test Type, 2020 to 2035
12.2.1. Cell-Free DNA Screening Test
12.2.2. Serum Marker Screening Test
12.2.3. Neural Tube Defects Test
12.2.4. Ultrasonography
12.3. Market Value Forecast By Product, 2020 to 2035
12.3.1. Instruments
12.3.2. Kits & Reagents
12.4. Market Value Forecast By Technology, 2020 to 2035
12.4.1. Whole-Genome Sequencing
12.4.2. SNP Analysis
12.4.3. Microarray Analysis
12.4.4. Rolling Circle Amplification
12.5. Market Value Forecast By Indication, 2020 to 2035
12.5.1. Down Syndrome (trisomy 21)
12.5.2. Edwards syndrome (trisomy 18)
12.5.3. Patau syndrome (trisomy 13)
12.5.4. Turner Syndrom (Monosomy X/XO)
12.5.5. Klinefelter Syndrome (XXY)
12.5.6. Jacob's Syndrome (XYY)
12.5.7. Gender Identification
12.5.8. Others (Triple X, etc.)
12.6. Market Value Forecast By End-user, 2020 to 2035
12.6.1. Hospitals
12.6.2. Specialty Clinics
12.6.3. Diagnostics Laboratories
12.6.4. Others (Research Institutes, etc.)
12.7. Market Value Forecast By Country, 2020 to 2035
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Test Type
12.8.2. By Product
12.8.3. By Technology
12.8.4. By Indication
12.8.5. By End-user
12.8.6. By Country
13. Europe Non-invasive Prenatal Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Test Type, 2020 to 2035
13.2.1. Cell-Free DNA Screening Test
13.2.2. Serum Marker Screening Test
13.2.3. Neural Tube Defects Test
13.2.4. Ultrasonography
13.3. Market Value Forecast By Product, 2020 to 2035
13.3.1. Instruments
13.3.2. Kits & Reagents
13.4. Market Value Forecast By Technology, 2020 to 2035
13.4.1. Whole-Genome Sequencing
13.4.2. SNP Analysis
13.4.3. Microarray Analysis
13.4.4. Rolling Circle Amplification
13.5. Market Value Forecast By Indication, 2020 to 2035
13.5.1. Down Syndrome (trisomy 21)
13.5.2. Edwards syndrome (trisomy 18)
13.5.3. Patau syndrome (trisomy 13)
13.5.4. Turner Syndrom (Monosomy X/XO)
13.5.5. Klinefelter Syndrome (XXY)
13.5.6. Jacob's Syndrome (XYY)
13.5.7. Gender Identification
13.5.8. Others (Triple X, etc.)
13.6. Market Value Forecast By End-user ,2020 to 2035
13.6.1. Hospitals
13.6.2. Specialty Clinics
13.6.3. Diagnostics Laboratories
13.6.4. Others (Research Institutes, etc.)
13.7. Market Value Forecast By Country/Sub-region ,2020 to 2035
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Test Type
13.8.2. By Product
13.8.3. By Technology
13.8.4. By Indication
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Non-invasive Prenatal Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Test Type, 2020 to 2035
14.2.1. Cell-Free DNA Screening Test
14.2.2. Serum Marker Screening Test
14.2.3. Neural Tube Defects Test
14.2.4. Ultrasonography
14.3. Market Value Forecast By Product, 2020 to 2035
14.3.1. Instruments
14.3.2. Kits & Reagents
14.4. Market Value Forecast By Technology, 2020 to 2035
14.4.1. Whole-Genome Sequencing
14.4.2. SNP Analysis
14.4.3. Microarray Analysis
14.4.4. Rolling Circle Amplification
14.5. Market Value Forecast By Indication, 2020 to 2035
14.5.1. Down Syndrome (trisomy 21)
14.5.2. Edwards syndrome (trisomy 18)
14.5.3. Patau syndrome (trisomy 13)
14.5.4. Turner Syndrom (Monosomy X/XO)
14.5.5. Klinefelter Syndrome (XXY)
14.5.6. Jacob's Syndrome (XYY)
14.5.7. Gender Identification
14.5.8. Others (Triple X, etc.)
14.6. Market Value Forecast By End-user, 2020 to 2035
14.6.1. Hospitals
14.6.2. Specialty Clinics
14.6.3. Diagnostics Laboratories
14.6.4. Others (Research Institutes, etc.)
14.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
14.7.1. China
14.7.2. India
14.7.3. Japan
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Test Type
14.8.2. By Product
14.8.3. By Technology
14.8.4. By Indication
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Non-invasive Prenatal Testing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Test Type, 2020 to 2035
15.2.1. Cell-Free DNA Screening Test
15.2.2. Serum Marker Screening Test
15.2.3. Neural Tube Defects Test
15.2.4. Ultrasonography
15.3. Market Value Forecast By Product, 2020 to 2035
15.3.1. Instruments
15.3.2. Kits & Reagents
15.4. Market Value Forecast By Technology ,2020 to 2035
15.4.1. Whole-Genome Sequencing
15.4.2. SNP Analysis
15.4.3. Microarray Analysis
15.4.4. Rolling Circle Amplification
15.5. Market Value Forecast By Indication, 2020 to 2035
15.5.1. Down Syndrome (trisomy 21)
15.5.2. Edwards syndrome (trisomy 18)
15.5.3. Patau syndrome (trisomy 13)
15.5.4. Turner Syndrom (Monosomy X/XO)
15.5.5. Klinefelter Syndrome (XXY)
15.5.6. Jacob's Syndrome (XYY)
15.5.7. Gender Identification
15.5.8. Others (Triple X, etc.)
15.6. Market Value Forecast By End-user, 2020 to 2035
15.6.1. Hospitals
15.6.2. Specialty Clinics
15.6.3. Diagnostics Laboratories
15.6.4. Others (Research Institutes, etc.)
15.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Test Type
15.8.2. By Product
15.8.3. By Technology
15.8.4. By Indication
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Non-invasive Prenatal Testing Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Test Type, 2020 to 2035
16.2.1. Cell-Free DNA Screening Test
16.2.2. Serum Marker Screening Test
16.2.3. Neural Tube Defects Test
16.2.4. Ultrasonography
16.3. Market Value Forecast By Product, 2020 to 2035
16.3.1. Instruments
16.3.2. Kits & Reagents
16.4. Market Value Forecast By Technology, 2020 to 2035
16.4.1. Whole-Genome Sequencing
16.4.2. SNP Analysis
16.4.3. Microarray Analysis
16.4.4. Rolling Circle Amplification
16.5. Market Value Forecast By Indication, 2020 to 2035
16.5.1. Down Syndrome (trisomy 21)
16.5.2. Edwards syndrome (trisomy 18)
16.5.3. Patau syndrome (trisomy 13)
16.5.4. Turner Syndrom (Monosomy X/XO)
16.5.5. Klinefelter Syndrome (XXY)
16.5.6. Jacob's Syndrome (XYY)
16.5.7. Gender Identification
16.5.8. Others (Triple X, etc.)
16.6. Market Value Forecast By End-user, 2020 to 2035
16.6.1. Hospitals
16.6.2. Specialty Clinics
16.6.3. Diagnostics Laboratories
16.6.4. Others (Research Institutes, etc.)
16.7. Market Value Forecast By Country/Sub-region ,2020 to 2035
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Test Type
16.8.2. By Product
16.8.3. By Technology
16.8.4. By Indication
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2024)
17.3. Company Profiles
17.3.1. F. Hoffmann-La Roche Ltd
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. Natera, Inc.
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. Illumina, Inc
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. PerkinElmer Inc.
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Eurofins LifeCodexx AG
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. IGENOMIX
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. Pacific Biosciences
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. BGI
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Laboratory Corporation of America Holdings
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. Agilent Technologies, Inc.
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments
17.3.11. Berry Genetics Inc.
17.3.11.1. Company Overview
17.3.11.2. Financial Overview
17.3.11.3. Product Portfolio
17.3.11.4. Business Strategies
17.3.11.5. Recent Developments
List of Tables
Table 01: Global Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Test Type, 2020 to 2035
Table 02: Global Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Product, 2020 to 2035
Table 03: Global Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 04: Global Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 05: Global Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 06: Global Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 07: North America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
Table 08: North America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Test Type, 2020 to 2035
Table 09: North America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Product, 2020 to 2035
Table 10: North America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 11: North America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 12: North America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 13: Europe - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 14: Europe - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Test Type, 2020 to 2035
Table 15: Europe - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Product, 2020 to 2035
Table 16: Europe - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 17: Europe - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 18: Europe - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 19: Asia Pacific - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 20: Asia Pacific - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Test Type, 2020 to 2035
Table 21: Asia Pacific - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Product, 2020 to 2035
Table 22: Asia Pacific - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 23: Asia Pacific - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 24: Asia Pacific - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 25: Latin America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 26: Latin America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Test Type, 2020 to 2035
Table 27: Latin America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Product, 2020 to 2035
Table 28: Latin America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 29: Latin America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 30: Latin America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 31: Middle East & Africa - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 32: Middle East & Africa - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Test Type, 2020 to 2035
Table 33: Middle East & Africa - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Product, 2020 to 2035
Table 34: Middle East & Africa - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 35: Middle East & Africa - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 36: Middle East & Africa - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
List of Figures
Figure 01: Global Non-invasive Prenatal Testing Market Value Share Analysis, By Test Type, 2024 and 2035
Figure 02: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, By Test Type, 2025 to 2035
Figure 03: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Cell-Free DNA Screening Test, 2020 to 2035
Figure 04: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Serum Marker Screening Test, 2020 to 2035
Figure 05: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Neural Tube Defects Test, 2020 to 2035
Figure 06: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Ultrasonography, 2020 to 2035
Figure 07: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Weight Management, 2020 to 2035
Figure 08: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Nutrition, 2020 to 2035
Figure 09: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 10: Global Non-invasive Prenatal Testing Market Value Share Analysis, By Product, 2024 and 2035
Figure 11: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, By Product, 2025 to 2035
Figure 12: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Instruments, 2020 to 2035
Figure 13: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Kits & Reagents, 2020 to 2035
Figure 14: Global Non-invasive Prenatal Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 15: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 16: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Whole-Genome Sequencing, 2020 to 2035
Figure 17: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by SNP Analysis, 2020 to 2035
Figure 18: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Microarray Analysis, 2020 to 2035
Figure 19: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Rolling Circle Amplification, 2020 to 2035
Figure 20: Global Non-invasive Prenatal Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 21: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 22: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Down Syndrome (trisomy 21), 2020 to 2035
Figure 23: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Edwards syndrome (trisomy 18), 2020 to 2035
Figure 24: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Patau syndrome (trisomy 13), 2020 to 2035
Figure 25: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Turner Syndrom (Monosomy X/XO), 2020 to 2035
Figure 26: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Klinefelter Syndrome (XXY), 2020 to 2035
Figure 27: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Jacob's Syndrome (XYY), 2020 to 2035
Figure 28: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Gender Identification, 2020 to 2035
Figure 29: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 30: Global Non-invasive Prenatal Testing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 31: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, By End-user 2025 to 2035
Figure 32: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Hospitals, 2020 to 2035
Figure 33: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Diagnostics Laboratories, 2020 to 2035
Figure 34: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Specialty Clinics, 2020 to 2035
Figure 35: Global Non-invasive Prenatal Testing Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 36: Global Non-invasive Prenatal Testing Market Value Share Analysis, By Region, 2024 and 2035
Figure 37: Global Non-invasive Prenatal Testing Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 38: North America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 39: North America - Non-invasive Prenatal Testing Market Value Share Analysis, by Country, 2024 and 2035
Figure 40: North America - Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 41: North America - Non-invasive Prenatal Testing Market Value Share Analysis, By Test Type, 2024 and 2035
Figure 42: North America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Test Type, 2025 to 2035
Figure 43: North America - Non-invasive Prenatal Testing Market Value Share Analysis, By Product, 2024 and 2035
Figure 44: North America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Product, 2025 to 2035
Figure 45: North America - Non-invasive Prenatal Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 46: North America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 47: North America - Non-invasive Prenatal Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 48: North America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 49: North America - Non-invasive Prenatal Testing Market Value Share Analysis, By End-user 2024 and 2035
Figure 50: North America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 51: Europe - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 52: Europe - Non-invasive Prenatal Testing Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 53: Europe - Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 54: Europe - Non-invasive Prenatal Testing Market Value Share Analysis, By Test Type, 2024 and 2035
Figure 55: Europe - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Test Type, 2025 to 2035
Figure 56: Europe - Non-invasive Prenatal Testing Market Value Share Analysis, By Product, 2024 and 2035
Figure 57: Europe - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Product, 2025 to 2035
Figure 58: Europe - Non-invasive Prenatal Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 59: Europe - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 60: Europe - Non-invasive Prenatal Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 61: Europe - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 62: Europe - Non-invasive Prenatal Testing Market Value Share Analysis, By End-user 2024 and 2035
Figure 63: Europe - Non-invasive Prenatal Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 64: Asia Pacific - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 65: Asia Pacific - Non-invasive Prenatal Testing Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 66: Asia Pacific - Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 67: Asia Pacific - Non-invasive Prenatal Testing Market Value Share Analysis, By Test Type, 2024 and 2035
Figure 68: Asia Pacific - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Test Type, 2025 to 2035
Figure 69: Asia Pacific - Non-invasive Prenatal Testing Market Value Share Analysis, By Product, 2024 and 2035
Figure 70: Asia Pacific - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Product, 2025 to 2035
Figure 71: Asia Pacific - Non-invasive Prenatal Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 72: Asia Pacific - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 73: Asia Pacific - Non-invasive Prenatal Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 74: Asia Pacific - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 75: Asia Pacific - Non-invasive Prenatal Testing Market Value Share Analysis, By End-user 2024 and 2035
Figure 76: Asia Pacific - Non-invasive Prenatal Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 77: Latin America - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 78: Latin America - Non-invasive Prenatal Testing Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 79: Latin America - Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 80: Latin America - Non-invasive Prenatal Testing Market Value Share Analysis, By Test Type, 2024 and 2035
Figure 81: Latin America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Test Type, 2025 to 2035
Figure 82: Latin America - Non-invasive Prenatal Testing Market Value Share Analysis, By Product, 2024 and 2035
Figure 83: Latin America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Product, 2025 to 2035
Figure 84: Latin America - Non-invasive Prenatal Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 85: Latin America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 86: Latin America - Non-invasive Prenatal Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 87: Latin America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 88: Latin America- Non-invasive Prenatal Testing Market Value Share Analysis, By End-user 2024 and 2035
Figure 89: Latin America - Non-invasive Prenatal Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 90: Middle East & Africa - Non-invasive Prenatal Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 91: Middle East & Africa - Non-invasive Prenatal Testing Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 92: Middle East & Africa - Non-invasive Prenatal Testing Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 93: Middle East & Africa - Non-invasive Prenatal Testing Market Value Share Analysis, By Test Type, 2024 and 2035
Figure 94: Middle East & Africa - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Test Type, 2025 to 2035
Figure 95: Middle East & Africa - Non-invasive Prenatal Testing Market Value Share Analysis, By Product, 2024 and 2035
Figure 96: Middle East & Africa - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Product, 2025 to 2035
Figure 97: Middle East & Africa - Non-invasive Prenatal Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 98: Middle East & Africa - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 99: Middle East & Africa - Non-invasive Prenatal Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 100: Middle East & Africa - Non-invasive Prenatal Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 101: Middle East & Africa - Non-invasive Prenatal Testing Market Value Share Analysis, By End-user 2024 and 2035
Figure 102: Middle East & Africa - Non-invasive Prenatal Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Non-invasive Prenatal Testing Market